Impact of preexisting vector-specific immunity on vaccine potency: Characterization of Listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice

Infection and Immunity

Volumn 77, Issue 9, 2009, Pages 3958-3968

  Leong, Meredith L ^a,b,c   Hampl, Johannes ^a   Liu, Weiqun ^a,d   Mathur, Shruti ^a   Bahjat, Keith S ^a,f   Luckett, William ^a   Dubensky Jr , Thomas W ^a,e   Brockstedt, Dirk G ^a,b,c  

^a Anza Therapeutics Inc   (United States)

^b Aduro BioTech Inc   (United States)

^c Cerus Corporation ^*  (United States)

^d CERUS CORPORATION   (United States)

^e Immune Design Corp   (United States)

^f PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; LISTERIA MONOCYTOGENES VACCINE; LISTERIOLYSIN O; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMORAL IMMUNITY; LISTERIA MONOCYTOGENES; LISTERIOSIS; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; BACTERIAL VACCINES; CELL LINE; FEMALE; GENETIC VECTORS; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; HUMANS; INTERLEUKIN-2; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 69049109882     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01274-08     Document Type: Article

References (44)

1. Attridge, S. R., and C. J. Vindurampulle. 2005. Vector-primed mice display hypo-responsiveness to foreign antigen presented by recombinant Salmonella regardless of the route of delivery. Microb. Pathog. 39:1-7.
2. Barouch, D. H., M. G. Pau, J. H. Custers, W. Koudstaal, S. Kostense, M. J. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, B. Korioth-Schmitz, M. H. Newberg, D. A. Gorgone, M. A. Lifton, D. L. Panicali, G. J. Nabel, N. L. Letvin, and J. Goudsmit. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297.
3. Reference deleted.
4. Bishop, D. K., and D. J. Hinrichs. 1987. Adoptive transfer of immunity to Listeria monocytogenes. The influence of in vitro stimulation on lymphocyte subset requirements. J. Immunol. 139:2005-2009.
5. Bouwer, H. G., H. Shen, X. Fan, J. F. Miller, R. A. Barry, and D. J. Hinrichs. 1999. Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response. Infect. Immun. 67:253-258.
6. Brave, A., K. Ljungberg, B. Wahren, and M. A. Liu. 2007. Vaccine delivery methods using viral vectors. Mol. Pharm. 4:18-32.
7. Breckpot, K., J. L. Aerts, and K. Thielemans. 2007. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther. 14:847-862.
8. Brockstedt, D. G., K. S. Bahjat, M. A. Giedlin, W. Liu, M. Leong, W. Luckett, Y. Gao, P. Schnupf, D. Kapadia, G. Castro, J. Y. Lim, A. Sampson-Johannes, A. A. Herskovits, A. Stassinopoulos, H. G. Bouwer, J. E. Hearst, D. A. Portnoy, D. N. Cook, and T. W. Dubensky. 2005. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat. Med. 11:853-860.
9. Brockstedt, D. G., M. A. Giedlin, M. L. Leong, K. S. Bahjat, Y. Gao, W. Luckett, W. Liu, D. N. Cook, D. A. Portnoy, and T. W. Dubensky, Jr. 2004. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 101:13832-13837.
10. Camilli, A., L. G. Tilney, and D. A. Portnoy. 1993. Dual roles of plcA in Listeria monocytogenes pathogenesis. Mol. Microbiol. 8:143-157.
11. Casimiro, D. R., L. Chen, T. M. Fu, R. K. Evans, M. J. Caulfield, M. E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, D. C. Freed, K. A. Wilson, S. Dubey, D. M. Zhu, D. Nawrocki, H. Mach, R. Troutman, L. Isopi, D. Williams, W. Hurni, Z. Xu, J. G. Smith, S. Wang, X. Liu, L. Guan, R. Long, W. Trigona, G. J. Heidecker, H. C. Perry, N. Persaud, T. J. Toner, Q. Su, X. Liang, R. Youil, M. Chastain, A. J. Bett, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313.
12. Cohen, P. 2006. Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response. IAVI Rep. 10:1-5.
13. Cossart, P., and M. Lecuit. 1998. Interactions of Listeria monocytogenes with mammalian cells during entry and actin-based movement: bacterial factors, cellular ligands and signaling. EMBO J. 17:3797-3806.
14. Cossart, P., J. Pizarro-Cerda, and M. Lecuit. 2003. Invasion of mammalian cells by Listeria monocytogenes: functional mimicry to subvert cellular functions. Trends Cell Biol. 13:23-31.
15. Dudek, T., and D. M. Knipe. 2006. Replication-defective viruses as vaccines and vaccine vectors. Virology 344:230-239.
16. Edelson, B. T., P. Cossart, and E. R. Unanue. 1999. Paradigm revisited: antibody provides resistance to Listeria infection. J. Immunol. 163:4087-4090.
17. Edelson, B. T., and E. R. Unanue. 2001. Intracellular antibody neutralizes Listeria growth. Immunity 14:503-512.
18. Farber, J. M., and P. I. Peterkin. 1991. Listeria monocytogenes, a food-borne pathogen. Microbiol. Rev. 55:476-511.
19. Fattori, E., I. Zampaglione, M. Arcuri, A. Meola, B. B. Ercole, A. Cirillo, A. Folgori, A. Bett, M. Cappelletti, E. Sporeno, R. Cortese, A. Nicosia, and S. Colloca. 2006. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther. 13:1088-1096.
20. Friedman, R. S., F. R. Frankel, Z. Xu, and J. Lieberman. 2000. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J. Virol. 74:9987-9993.
21. Geginat, G., S. Schenk, M. Skoberne, W. Goebel, and H. Hof. 2001. A novel approach of direct ex vivo epitope mapping identifies dominant and subdominant CD4 and CD8 T cell epitopes from Listeria monocytogenes. J. Immunol. 166:1877-1884.
22. Gentschev, I., Z. Sokolovic, S. Kohler, G. F. Krohne, H. Hof, J. Wagner, and W. Goebel. 1992. Identification of p60 antibodies in human sera and presentation of this listerial antigen on the surface of attenuated salmonellae by the HlyB-HlyD secretion system. Infect. Immun. 60:5091-5098.
23. + T cells. Infect. Immun. 63:2288-2294.
24. Hage-Chahine, C. M., G. Del Giudice, P. H. Lambert, and J. C. Pechere. 1992. Hemolysin-producing Listeria monocytogenes affects the immune response to T-cell-dependent and T-cell-independent antigens. Infect. Immun. 60:1415-1421.
25. Kolb-Maurer, A., I. Gentschev, H. W. Fries, F. Fiedler, E. B. Brocker, E. Kampgen, and W. Goebel. 2000. Listeria monocytogenes-infected human dendritic cells: uptake and host cell response. Infect. Immun. 68:3680-3688.
26. Kolb-Maurer, A., S. Pilgrim, E. Kampgen, A. D. McLellan, E. B. Brocker, W. Goebel, and I. Gentschev. 2001. Antibodies against listerial protein 60 act as an opsonin for phagocytosis of Listeria monocytogenes by human dendritic cells. Infect. Immun. 69:3100-3109.
27. Lauer, P., M. Y. Chow, M. J. Loessner, D. A. Portnoy, and R. Calendar. 2002. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J. Bacteriol. 184:4177-4186.
28. Lecuit, M. 2005. Understanding how Listeria monocytogenes targets and crosses host barriers. Clin. Microbiol. Infect. 11:430-436.
29. Lemckert, A. A., S. M. Sumida, L. Holterman, R. Vogels, D. M. Truitt, D. M. Lynch, A. Nanda, B. A. Ewald, D. A. Gorgone, M. A. Lifton, J. Goudsmit, M. J. Havenga, and D. H. Barouch. 2005. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J. Virol. 79:9694-9701.
30. Naslund, T. I., C. Uyttenhove, E. K. Nordstrom, D. Colau, G. Warnier, M. Jondal, B. J. Van den Eynde, and P. Liljestrom. 2007. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. 178:6761-6769.
31. O'Riordan, M., C. H. Yi, R. Gonzales, K. D. Lee, and D. A. Portnoy. 2002. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc. Natl. Acad. Sci. USA 99:13861-13866.
32. Pashen, A., M. Song, S. Schenk, J. Janda, X. D. Nguyen, W. Osen, D. Schadendorf, and G. Geginat. 2006. Identification of a cross-reactive HLA-DRB1* 0301-restricted CD4 T cell response directed against cholestrol-binding cytolysins from two different pathogens. Microbes Infect. 8:2034-2043.
33. Pizarro-Cerda, J., and P. Cossart. 2006. Subversion of cellular functions by Listeria monocytogenes. J. Pathol. 208:215-223.
34. Prussin, C., and D. D. Metcalfe. 1995. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J. Immunol. Methods. 188:117-128.
35. Roberts, D. M., A. Nanda, M. J. Havenga, P. Abbink, D. M. Lynch, B. A. Ewald, J. Liu, A. R. Thorner, P. E. Swanson, D. A. Gorgone, M. A. Lifton, A. A. Lemckert, L. Holterman, B. Chen, A. Dilraj, A. Carville, K. G. Mans-field, J. Goudsmit, and D. H. Barouch. 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239-243.
36. Reference deleted.
37. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13:529-538.
38. Starks, H., K. W. Bruhn, H. Shen, R. A. Barry, T. W. Dubensky, D. Brockstedt, D. J. Hinrichs, D. E. Higgins, J. F. Miller, M. Giedlin, and H. G. Bouwer. 2004. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J. Immunol. 173:420-427.
39. Stevens, R., A. Lavoy, S. Nordone, M. Burkhard, and G. A. Dean. 2005. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine. Vaccine 23:1479-1490.
40. Sumida, S. M., D. M. Truitt, M. G. Kishko, J. C. Arthur, S. S. Jackson, D. A. Gorgone, M. A. Lifton, W. Koudstaal, M. G. Pau, S. Kostense, M. J. Havenga, J. Goudsmit, N. L. Letvin, and D. H. Barouch. 2004. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78:2666-2673.
41. +-T-cell response to secreted and nonsecreted antigens delivered by recombinant Listeria monocytogenes during secondary infection. Infect. Immun. 70:153-162.
42. Vijh, S., I. M. Pilip, and E. G. Pamer. 1999. Noncompetitive expansion of cytotoxic T lymphocytes specific for different antigens during bacterial infection. Infect. Immun. 67:1303-1309.
43. Ye, M., S. Kasey, S. Khurana, N. T. Nguyen, S. Schubert, C. T. Nugent, K. Kuus-Reichel, and J. Hampl. 2004. MHC class II tetramers containing influenza hemagglutinin and EBV EBNA1 epitopes detect reliably specific CD4(+) T cells in healthy volunteers. Hum. Immunol. 65:507-513.
44. Yoshimura, K., A. Jain, H. E. Allen, L. S. Laird, C. Y. Chia, S. Ravi, D. G. Brockstedt, M. A. Giedlin, K. S. Bahjat, M. L. Leong, J. E. Slansky, D. N. Cook, T. W. Dubensky, D. M. Pardoll, and R. D. Schulick. 2006. Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res. 66:1096-1104.